2003年4月1日 · Diabetic ketoacidosis (DKA) and the hyperglycemic hyperosmolar state (HHS) appear as 2 extremes in the spectrum of diabetic decompensation. 1 They remain the most serious acute metabolic complications of diabetes mellitus and …

2018年6月25日 · Sodium–glucose cotransporter-2 (SGLT-2) inhibitors have been associated with euglycemic diabetic ketoacidosis. Precipitants to ketoacidosis include intercurrent illnesses, surgery, decreased carbohydrate intake, dehydration and excessive alcohol intake.

Clinical diagnosis is based on the finding of dehydration along with high capillary glucose levels with or without ketones in the urine or plasma. The diagnosis is confirmed by the blood pH, serum bicarbonate level and serum osmolality.

2003年4月1日 · Clinical diagnosis is based on the finding of dehydration along with high capillary glucose levels with or without ketones in the urine or plasma. The diagnosis is confirmed by the blood pH, serum bicarbonate level and serum osmolality.

2018年6月25日 · Euglycemic diabetic ketoacidosis associated with the use of a sodium-glucose cotransporter-2 inhibitor CMAJ . 2018 Jun 25;190(25):E766-E768. doi: 10.1503/cmaj.171319.

2018年4月9日 · Background: Diabetic ketoacidosis is the leading cause of death among children with type 1 diabetes mellitus, and is an avoidable complication at first-time diagnosis of diabetes. Because having a usual provider of primary care is important in improving health outcomes for children, we tested the association between having a usual provider of ...

2021年6月1日 · Diabetic ketoacidosis (DKA) is a form of a hyperglycemic emergency mainly characterized by the triad of hyperglycemia, ketosis, and anion gap metabolic acidosis. DKA may be the initial presentation in approximately 25-40 % of patients with type 1 diabetes. It may also occur in at least 34% of patients with type 2 diabetes.

2021年9月7日 · Use of sodium-glucose co-transporter 2 (SGLT-2) inhibitors is currently classified as off-label in individuals less than 18 years of age in Canada. Use of SGLT-2 inhibitors may result in euglycemic diabetic ketoacidosis (DKA) in patients who are insulin dependent and have intercurrent illness.

2022年10月1日 · Despite the numerous benefits of SGLT2 inhibitors on cardiac health, they can be associated with an increased risk of diabetic ketoacidosis, often with normal glucose levels (euglycemic diabetic ketoacidosis or EDKA), which potentially can be detrimental in this vulnerable patient population.

2019年6月1日 · Diabetic ketoacidosis (DKA) is associated with significant morbidity and mortality. Using standardized protocols for DKA management improves outcomes and is recommended in Diabetes Canada’s clinical practice guidelines. Audits of DKA care at our institution revealed inconsistent management.